Need professional-grade analysis? Visit stockanalysis.com
$3.17B
N/A
146
N/A
Edgewise Therapeutics Inc (EWTX) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $32.45, down 5.75% from the previous close.
Over the past year, EWTX has traded between a low of $12.61 and a high of $34.43. The stock has gained 118.8% over this period. It is currently 5.8% below its 52-week high.
Edgewise Therapeutics Inc has a market capitalization of $3.17B.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Side-by-side comparison against top Healthcare peers.